CNSP News and Press, CNS Pharmaceuticals Inc. From 09/07/22

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million The company clos...

Tumors remain one of the deadliest diseases in the world, accounting for around one in six deaths globally in 2020. While scientists may not have found a cure for life-threatening tumors despite decades of research, there are a variety of treatments that can reduce and even eliminate tumor...

CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire HOUSTON , Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company speci...

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fas...

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive...

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new pat...

As of 2020, an estimated 18.8 million people worldwide had cancer. The deadly disease takes millions of lives each year, with the United States losing more than 600,000 yearly to cancer deaths. Although scientists have worked tirelessly for years to develop a cure for cancer with little su...

CNS Pharmaceuticals press release ( NASDAQ: CNSP ): Q2 Net Loss of $3.6M As of June 30, 2022, the company had cash of approximately $9M and working capital of approximately $10.5M. The company's current expectation is that the cash on hand and the proceeds from the offerin...

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme ("GBM") ...

Cancer is one of the deadliest diseases on the planet. It affects millions of people across the world, takes more than 10 million lives every year , and still doesn’t have a cure. Most cancer-management therapies involve treatments such as chemotherapy, surgery, radiation therapy and...